Outpatient Medication Costs of Patients with Cystic Fibrosis in Germany

Eidt-Koch, Daniela; Wagner, Thomas; Mittendorf, Thomas; Schulenburg, J.-Matthias Graf von der

doi:10.2165/11313980-000000000-00000

Cited by 20 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the economic impact of CF has also increased over the past three decades. Many costs of illness studies have been conducted in Europe and the United States (U.S) (17)(18)(19)(20)(21)(22)(23)(24)(25)(26).…”

Section: Introductionmentioning

confidence: 99%

“…Cost estimates for treatment based on data collected through regional CF centres, medical records, patient questionnaires, clinical trial and insurance claims or CF specific databases over the last three decades have demonstrated variable results. A wide range in costs, evaluated populations and different methodological approaches to calculate costs were also evident (17)(18)(19)(20)(21)(22)(23)(24)(25)(26). Where stated, medical drug treatment costs have contributed to anywhere between 12 to 85% of total costs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Health economic modelling in Cystic Fibrosis: A systematic review

Mohindru

Turner

Sach

et al. 2019

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Introduction: Cystic Fibrosis (CF) is a heritable chronic condition. Due to the genetic and progressive nature of CF, a number of interventions are available for the condition. In the United Kingdom (U.K.) average cost of CF treatment is between €49,000 to €76,000 1 per patient (1). A review of health economic modelling studies is warranted to provide decision makers and researchers with an in depth understanding of modelling practices in CF and guidance for future research.Methods: Online searches were performed in the 5 databases, studies were included if they were: 1) Model based economic evaluation for management of Cystic Fibrosis.Articles were restricted to English language only, but no restriction was applied on publication year.Results: Nine studies were reviewed, most were Markov cohort models. Models evaluated pharmaceutical interventions and drug adherence. Modelling structure was consistent across most articles and a range of sources were used to populate the models. Cost and utility data were based on different sources and elicitation methods respectively. The majority of models failed to incorporate significant health events which impact both cost and disease progression. 1 2012

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Health economic modelling in Cystic Fibrosis: A systematic review

Mohindru

Turner

Sach

et al. 2019

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

show abstract

“…The findings are significant from multiple perspectives. For instance, the associated annual pharmacological treatment costs associated with CF in adults (>17) is an estimated € 21,603 per patient/year (Eidt-Koch, Wagner, Mittenford & Graf von der Schulenburg, 2010). Our findings bolster the need to expand tobacco cessation programs available to CF patients.…”

Section: Discussionmentioning

confidence: 99%

Long term follow-up of a tobacco prevention and cessation program in cystic fibrosis patients

et al. 2016

View full text Add to dashboard Cite

This study evaluates the impact over time of a telephone-based intervention in tobacco cessation and prevention targeting patients with cystic fibrosis (CF) in the Mediterranean region of Murcia, Spain. We conducted an experimental prospective study with a cohort of CF patients using an integrative smoking cessation programme, between 2008 and 2013. The target population included family members and patients from the Regional CF unit. The study included an initial tobacco exposure questionnaire, measurement of lung function, urinary cotinine levels, anthropomorphic measures and the administered intervention at specific time intervals. Of the 88 patients tracked through follow-up, active smoking rates were reduced from 10.23% to 4.55% (p = 0.06). Environmental tobacco exposure was reduced in non-smoker patients from 62.03% to 36.90% (p < 0.01) during the five year follow-up. Significant reductions in the gradient of household tobacco smoke exposure were also observed with a decrease of 12.60%, from 31.65% (n = 25/79) to 19.05% (n = 16/84) in 2013 (p = <0.01). Cotinine was significantly correlated with both active and passive exposure (p<0.01) with a significant reduction of cotinine levels from 63.13 (28.58–97.69) to 20.56 (0.86–40.27) ng/ml (p<0.01). The intervention to significantly increase the likelihood of family quitting (smoke-free home) was 1.26 (1.05–1.54). Telephone based interventions for tobacco cessation and prevention is a useful tool when applied over time. Trained intervention professionals in this area are needed in the environmental health approach for the treatment of CF.

show abstract

“…Hence, a lot of these specialized care units are underfunded, and there are fewer economic incentives for hospitals to provide high-quality care for patients with rare diseases. Moreover, a study calculated mean annual outpatient costs for medication at 21,603 euro per patient [8]. These examples show why health care for people with rare diseases is costly, and that there are too few resources for treatment in some cases.…”

Section: Rare Diseases From An Economic Point Of Viewmentioning

confidence: 99%